85. Idiopathic interstitial pneumonia Clinical trials / Disease details
Clinical trials : 598 / Drugs : 435 - (DrugBank : 116) / Drug target genes : 100 - Drug target pathways : 210
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01417156 (ClinicalTrials.gov) | September 2011 | 15/8/2011 | Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174) | A Phase II Open Label, Follow up Study to Investigate the Long Term Tolerability and Safety of Oral BIBF 1120 on Top of Pirfenidone in Japanese Patients With Idiopathic Pulmonary Fibrosis | Pulmonary Fibrosis | Drug: Nintedanib;Drug: Pirfenidoneone | Boehringer Ingelheim | NULL | Completed | 40 Years | N/A | All | 20 | Phase 2 | Japan |